Material
Peptide blend
Recovery research
KLOW80 MG
BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg + KPV 10 mg per vial. Direct evidence for the finished blend remains limited.
Product code KL080
MaterialPeptide blend
Research contextComposite peptide research.
Veyvanta / profile
Compound profile
* Vial labels may use shortened names to keep the label legible. The full material and composition are stated in this profile.
Composition
BPC-157 10 MG + GHK-Cu 50 MG + TB-500 10 MG + KPV 10 MG.
Research context
Composite peptide research.
Research interest
Why it draws attention
KLOW combines four component-level research themes spanning BPC-157, copper-peptide biology, thymosin-related remodeling, and KPV inflammatory signaling.
Signals researchers are following
- 01
Tissue, extracellular-matrix, and inflammatory models
- 02
Copper-peptide, thymosin-related, and KPV signaling
Evidence levelComponent-level evidence
Published evidence / research profile
What the published research shows
A source-led view of the findings reported to date, the maturity of the evidence, and the limits that matter when interpreting it.
Evidence levelComponent-level evidence
Common research directions
- Tissue, extracellular-matrix, and inflammatory models
- Copper-peptide, thymosin-related, and KPV signaling
Reported findings
The individual components have separate preclinical literatures: BPC-157 in repair models, GHK-Cu in connective tissue, thymosin beta 4 in wound biology, and KPV in intestinal inflammation models. The KLOW blend itself has not been clinically studied.
How to read the evidence
Component findings cannot predict the combined blend. Thymosin beta 4 data are not direct evidence for TB-500, and KPV evidence is primarily cellular and animal.
Selected references
Pilot Human Safety Study of Intravenous BPC-157Altern Ther Health Med (2025)View sourceGHK Limits Metal-Induced Protein Aggregation and Cell StressMetallomics (2024)View sourceThymosin Beta 4 and Mitochondrial Transfer in Tissue GraftsFree Radic Biol Med (2025)View sourceBPC-157 and Rat Achilles Tendon HealingJ Orthop Res (2003)View sourceGHK-Cu and Connective Tissue in Experimental WoundsJ Clin Invest (1993)View sourceTopical Thymosin Beta 4 in Venous UlcersAnn N Y Acad Sci (2010)View sourceInflammation-Responsive KPV Delivery in Preclinical ModelsSci Adv (2026)View sourceKPV Uptake and Intestinal InflammationGastroenterology (2008)View source
This summary describes published research on the named material or its components. It does not establish safety, efficacy, equivalence, or suitability of this Veyvanta research product for human use.
Lab math
Reconstitution & measurement calculator
Convert a declared vial amount and diluent volume into nominal concentration, liquid volume, and the equivalent position on a U-100 scale.
Research product
Research productKLOW / 80 MG
Component mode calculates against one declared ingredient. Total mode calculates against the full declared blend mass.
Calculated measurement
Enter a positive diluent volume and target amount to calculate.
A calculation, not a protocol
This tool performs unit conversion only. It does not recommend an amount, frequency, route, diluent, handling method, or human use. Results assume ideal mixing and a U-100 scale of 100 units per mL; validated laboratory procedures and material-specific compatibility take priority.
Product & historical codes
Current batch record
The product code identifies this material and declared strength. Supplier lot, expiry and analytical documentation are recorded separately when available.
- Batch
- KL803
- Expiry
- 2/9/28
Veyvanta internal batch record.
Find a label code
Direct product QR
This permanent link opens this exact product and strength. It does not certify an individual vial.
veyvanta.com/p/KL080Recovery research
